关于知识产权 知识产权培训 树立尊重知识产权的风尚 知识产权外联 部门知识产权 知识产权和热点议题 特定领域知识产权 专利和技术信息 商标信息 工业品外观设计信息 地理标志信息 植物品种信息(UPOV) 知识产权法律、条约和判决 知识产权资源 知识产权报告 专利保护 商标保护 工业品外观设计保护 地理标志保护 植物品种保护(UPOV) 知识产权争议解决 知识产权局业务解决方案 知识产权服务缴费 谈判与决策 发展合作 创新支持 公私伙伴关系 人工智能工具和服务 组织简介 与产权组织合作 问责制 专利 商标 工业品外观设计 地理标志 版权 商业秘密 WIPO学院 讲习班和研讨会 知识产权执法 WIPO ALERT 宣传 世界知识产权日 WIPO杂志 案例研究和成功故事 知识产权新闻 产权组织奖 企业 高校 土著人民 司法机构 遗传资源、传统知识和传统文化表现形式 经济学 金融 无形资产 性别平等 全球卫生 气候变化 竞争政策 可持续发展目标 前沿技术 移动应用 体育 旅游 PATENTSCOPE 专利分析 国际专利分类 ARDI - 研究促进创新 ASPI - 专业化专利信息 全球品牌数据库 马德里监视器 Article 6ter Express数据库 尼斯分类 维也纳分类 全球外观设计数据库 国际外观设计公报 Hague Express数据库 洛迦诺分类 Lisbon Express数据库 全球品牌数据库地理标志信息 PLUTO植物品种数据库 GENIE数据库 产权组织管理的条约 WIPO Lex - 知识产权法律、条约和判决 产权组织标准 知识产权统计 WIPO Pearl(术语) 产权组织出版物 国家知识产权概况 产权组织知识中心 产权组织技术趋势 全球创新指数 世界知识产权报告 PCT - 国际专利体系 ePCT 布达佩斯 - 国际微生物保藏体系 马德里 - 国际商标体系 eMadrid 第六条之三(徽章、旗帜、国徽) 海牙 - 国际外观设计体系 eHague 里斯本 - 国际地理标志体系 eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange 调解 仲裁 专家裁决 域名争议 检索和审查集中式接入(CASE) 数字查询服务(DAS) WIPO Pay 产权组织往来账户 产权组织各大会 常设委员会 会议日历 WIPO Webcast 产权组织正式文件 发展议程 技术援助 知识产权培训机构 COVID-19支持 国家知识产权战略 政策和立法咨询 合作枢纽 技术与创新支持中心(TISC) 技术转移 发明人援助计划(IAP) WIPO GREEN 产权组织的PAT-INFORMED 无障碍图书联合会 产权组织服务创作者 WIPO Translate 语音转文字 分类助手 成员国 观察员 总干事 部门活动 驻外办事处 职位空缺 采购 成果和预算 财务报告 监督
Arabic English Spanish French Russian Chinese
法律 条约 判决 按管辖区浏览

挪威

NO111

返回

Gene Technology Act (Act No. 38 of April 2, 1993 relating to the Production and Use of Genetically Modified Organisms, etc.)

 Act of 2 April 1993 No. 38 Relating to the Production and Use of Genetically Modified Organisms, etc. (Gene Technology Act)

Gene Technology Act - regjeringen.no http://www.regjeringen.no/en/doc/Laws/Acts/Gene-Technology-Act.htm...

You are here: Government.no / Documents / Acts and regulations / Gene Technology Act

Act of 2 April 1993 No. 38 Relating to the Production and Use of Genetically Modified Organisms, etc. (Gene Technology Act)

This transaltion is based on the norwegian text with latest amendments of 17 june 2005.

Translation for information use only.

Chapter 1 General provisions § 1 Purpose of the Act The purpose of this Act is to ensure that the production and use of genetically modified organisms and the production of cloned animals take place in an ethically justifiable and socially acceptable manner, in accordance with the principle of sustainable development and without adverse effects on health and the environment.

§ 2 Substantive scope of the Act The Act applies to the production and use of genetically modified organisms. The Act also applies to the production of cloned vertebrates and crustaceans. The provisions of the Act relating to genetically modified organisms also apply to substances and products that consist of or contain genetically modified organisms.

Unless genetically modified organisms are used as parental organisms, the Act does not apply to the production of the following by means of cell technology:

a. genetically modified plant cells where the same result can be obtained by means of traditional breeding methods, or b. animal cells in culture where the cell material has been obtained from different individuals of the same species and the cells could have been

produced by natural reproduction,

or the use of such plant or animal cells.

Unless the purpose is to produce a cloned individual, the Act does not apply to cloning of genes, cells and tissues.

The Act does not apply to the production of cloned animals that are not genetically modified and that could also arise through natural biological processes.

§ 3 The territorial scope of the Act The Act applies within the realm, including Svalbard and Jan Mayen. The Act also applies to the Norwegian dependencies in Antarctica, within Norway's economic zone and on the Norwegian part of the continental shelf.

§ 3a Duty to submit notification when establishing gene technology activities abroad The King may issue regulations relating to a duty for persons or companies under Norwegian jurisdiction that establish gene technology activities abroad to submit notification of this. Gene technology activities means any activities that come within the substantive scope of the Act, cf section 2.

§ 4 Definitions For the purposes of this Act, the following terms shall have the following meanings:

a. microorganism: any microbiological entity, cellular or non‑cellular, that is capable of replication or of transferring genetic material b. genetically modified organism: a microorganism, plant or animal in which the genetic material has been altered by means of gene or cell

technology c. gene technology: techniques that involve the isolation, characterisation and modification of heritable material and its introduction into living

cells or viruses d. cell technology: techniques for the production of living cells with new combinations of genetic material by the fusion of two or more cells e. cloned animal: an animal that is genetically identical or almost identical to another animal f. animal cloning: any technique for producing animals with identical or almost identical genetic material.

Chapter 2 Contained use of genetically modified organisms § 5 Definition The term ”contained use” means any operation in which genetically modified organisms are produced, cultured, stored, destroyed or used in some other way in a closed system in which physical barriers are employed, either alone or together with other special containment measures, to limit their contact with humans and the environment, in order to ensure a high level of safety for the latter.

§ 6 Safety measures in contained use Contained use shall take place in laboratories and installations that are approved pursuant to the second paragraph, and in accordance with good microbiological practice. The user shall ensure that the necessary safety measures are taken to prevent adverse effects on health and the environment, including measures to limit the adverse effects of any unintended release of genetically modified organisms. Records shall be kept of all contained use of genetically modified organisms.

Laboratories and other installations for contained use of genetically modified organisms shall be approved by the King.

The King may issue regulations relating to safety measures for contained use and laying down further details concerning the duty to keep records.

The King may by regulations grant exemptions from the provisions of this section for specified types of teaching activity.

§ 7 Duty to submit notification or to obtain approval The contained use of genetically modified organisms shall be notified or approved in accordance with regulations issued by the King. Such regulations may provide for exemptions to be granted for specified types of teaching activity.

1 of 4 14.10.2011 08:24

Gene Technology Act - regjeringen.no http://www.regjeringen.no/en/doc/Laws/Acts/Gene-Technology-Act.htm...

Irrespective of any regulations issued pursuant to the first paragraph, approval is required for the following forms of contained use:

a. genetic modification of vertebrates resulting in heritable genetic alterations, except for experiments that are approved pursuant to section 21, first paragraph, of the Prevention of Cruelty to Animals Act

b. the transfer of human genetic material to animals, plants or microorganisms if this is not carried out as part of research or experiments for the purpose of identifying the structure, characteristics and functions of heritable material

c. the production and use of genetically modified organisms for placing on the market or other commercial use.

The King may by regulations decide that for specific types or quantities of genetically modified organisms, production such as is mentioned in litra c shall instead be subject to the duty to submit notification.

The provisions concerning the duty to submit notification and the requirement for approval pursuant to this section do not apply to the production and use of hybrid animal cells for the production of monoclonal antibodies or to the isolation of chromosomes and chromosome fragments.

§ 8 Impact assessment for contained use The King may require that any person that applies for approval for contained use shall ensure that an impact assessment is carried out to elucidate the impacts of any unintended release of genetically modified organisms. Section 11, first paragraph, second sentence, and second paragraph, apply correspondingly.

Chapter 3 Deliberate release of genetically modified organisms § 9 Definition The term "deliberate release" means any production and use of genetically modified organisms that is not considered to be contained use pursuant to section 5.

The following are among the activities that are considered to be deliberate release under the Act:

a) deliberate release of genetically modified organisms for research purposes (field experiments)

b) deliberate release of genetically modified organisms for commercial purposes, for remedial purposes and the like

c) use of genetically modified organisms in greenhouses, aquaculture facilities, animal accommodation and the like, unless the facility in question is approved for contained use as part of an approved laboratory or other installation

d) routine release of genetically modified organisms from contained use

e) disposal of waste containing living genetically modified organisms

f) placing on the market of a product consisting of or containing genetically modified organisms

g) import of genetically modified organisms

h) transport of genetically modified organisms

i) export.

§ 10 Requirements relating to approval The deliberate release of genetically modified organisms may only take place with the approval of the King. Deliberate release such as is mentioned in section 9, litrae a, b, c and f, shall as a general rule only take place according to a step-by-step procedure. A product may not be approved for placing on the market until it has been subject to satisfactory field testing in natural environments that will be affected by the intended use. Approval is not required for other deliberate release of a product that has been approved for placing on the market pursuant to this provision.

The deliberate release of genetically modified organisms may only be approved when there is no risk of adverse effects on health or the environment. In deciding whether or not to grant an application, considerable weight shall also be given to whether the deliberate release will be of benefit to society and is likely to promote sustainable development.

The King may by regulations decide that deliberate release pursuant to section 9, litrae g and h, may take place without prior approval if further conditions, including requirements for special packaging and labelling of the products, have been fulfilled. It may be decided that such release shall instead be subject to the duty to submit notification.

Neither approval nor notification is required for export, unless otherwise provided by regulations issued by the King.

The King may by regulations provide that specific types of genetically modified organisms may be released into certain specified environments without approval pursuant to the first sentence of the first paragraph. Such release shall instead be subject to the duty to submit notification.

Approval is not required for the placing on the market of a product that has been approved for placing on the market in another EEA state pursuant to the rules laid down in Annex XX, paragraph 25, of the EEA Agreement (Council Directive 90/220/EEC). The competent authorities under the present Act may nevertheless prohibit or limit such placing on the market if in their view it involves a risk to health or the environment or if placing on the market is otherwise in conflict with the purpose of this Act.

§ 11 Impact assessment Applications for the approval of deliberate release pursuant to section 10 shall include an impact assessment setting out the risk of adverse effects on health and the environment and other consequences of the release. The King may by regulations lay down provisions concerning inter alia the content of the assessment and exemptions from the duty to submit an assessment.

The King may also require further information and investigations in addition to the impact assessment before a decision is made on an application.

Chapter 3a. Cloning § 11a. Prohibition against the cloning of animals It is prohibited to clone vertebrates and crustaceans.

§ 11b. Exemptions The Ministry or the instance designated by the Ministry may on application grant exemptions from the prohibition of section 11a for cloning as part of basic biological and medical research or for medical purposes. It is a condition for granting exemptions for cloning for medical purposes that the objective is to find treatment methods and prophylactic measures for people and animals, and that there is a sound balance between considerations of animal ethics and the expected benefits.

The power to grant exemptions does not apply to cloning of primates.

Applications for exemptions shall weigh up the benefits of the project against the animal stress or suffering caused, including considerations of animal integrity, instincts and welfare. Any person who applies to produce cloned animals shall review existing alternative methods and give an account of these in the application.

2 of 4 14.10.2011 08:24

Gene Technology Act - regjeringen.no http://www.regjeringen.no/en/doc/Laws/Acts/Gene-Technology-Act.htm...

The King may issue regulations laying down further details concerning the content of applications for exemption.

§ 11c. Requirements relating to cloning activities Records shall be kept of all activities carried out in accordance with exemptions granted pursuant to section 11b, first paragraph. The authorities may require the disclosure of information on cloning carried out in accordance with exemptions granted pursuant to section 11b, first paragraph, for use in public registers of cloning activities.

Premises that are used for cloning carried out in accordance with exemptions granted pursuant to section 11b, first paragraph, shall be suitable for the purpose and equipped for the functions they are to carry out.

The King may by regulations lay down further requirements concerning such activities, further requirements concerning the duty to keep records and requirements concerning the information to be disclosed to the authorities for use in registers of cloning activities.

Chapter 4 Implementation of the Act. Enforcement provisions § 12 Relationship to the Freedom of Information Act The Freedom of Information Act applies to cases that are dealt with under the present Act. Notwithstanding the duty of secrecy, the following information shall, however, always be public, unless it comes within the scope of section 6, subsection 1, of the Freedom of Information Act:

a. the description of the genetically modified organism, the user's name and address, the purpose of the use and the location of use b. methods and plans for monitoring and emergency response c. assessments of foreseeable effects.

§ 13 Public consultation In cases where approval is required under the present Act, the competent authority may decide that a public consultation is to be held. The processing of applications for the deliberate release of genetically modified organisms shall always include public consultation. The public consultation shall be held well before a decision is made. It must be carried out in a way that ensures that the general public, and particularly interest groups who will be affected, are given access to relevant information and a real opportunity to make their opinions known. A decision to hold a public consultation shall be published.

§ 14 Labelling requirement The King may issue regulations relating to the labelling of products that consist of or contain genetically modified organisms or products from cloned animals.

§ 15 Conditions laid down in approval Conditions may be laid down in approval granted pursuant to sections 6, second paragraph, 7, or 10, or in an exemption granted pursuant to section 11b. These may include conditions relating to the choice of the technical procedures and other factor inputs that are best on the basis of health and environmental considerations, a duty to take out insurance or provide security for liability pursuant to sections 21 and 23, and measures for preventing and limiting possible adverse effects. Approval may be granted for a limited period of time.

§ 16 Alteration and withdrawal of approval The conditions attached to an approval may be altered by the King, and if necessary the approval may be withdrawn if:

a. the risk to health or the environment posed by the use in question proves to be greater than was foreseen when the use was approved, or b. new technology makes it possible to reduce the risk of adverse effects on health or the environment, or c. this otherwise follows from the rules for reversing decisions that are currently in force.

§ 17 Control and internal control systems The King will decide which instance shall be responsible for ensuring compliance with this Act and any decisions made pursuant thereto.

The King may issue regulations relating to internal control and internal control systems to ensure compliance with requirements laid down in or pursuant to this Act.

§ 18 Right of inspection The supervisory authority may inspect any place where activities that come within the scope of this Act are being carried out.. The supervisory authority may require documents and other material that may be of importance for the exercise of its duties pursuant to this Act to be submitted for its inspection.

§ 19 Duty to provide information Any person that carries out activities that come within the scope of this Act has a duty on orders from the supervisory authority and notwithstanding any duty of secrecy, to provide the supervisory authority with any necessary information to enable it to carry out its duties pursuant to this Act. Information may also be required from other public authorities, notwithstanding any duty of secrecy that otherwise applies.

The supervisory authority shall be notified immediately in the event of an accident or other unforeseen circumstances that arise during the production and use of genetically modified organisms.

§ 20 Order to stop activities The supervisory authority may give orders for any activity that is in conflict with the Act or any decision made pursuant thereto to be stopped immediately. The same applies if the production and use of genetically modified organisms pursuant to the Act or decisions made pursuant thereto prove to pose a risk of adverse effects on health or the environment. If necessary, an order to stop an activity may be implemented with the assistance of the police.

§ 21 Duty to avoid or limit damage If genetically modified organisms have entered the environment in conflict with the Act or decisions pursuant thereto, the person responsible for the activity shall take reasonable measures to avoid or limit damage and nuisance. The same applies if the genetically modified organisms have been deliberately released into the environment in accordance with decisions pursuant to this Act, and their use proves to involve a greater risk to health or the environment than foreseen when the use was approved. The supervisory authority may order the person responsible to retrieve or take other measures to control the organisms within a specified time limit, including measures to restore the environment to its initial state as far as possible. Measures pursuant to this provision may also be implemented on another person's property.

If orders given pursuant to the first paragraph are not carried out within the time limit specified, the supervisory authority may arrange for the measures to be implemented at the expense of the person responsible. The same applies if giving an order pursuant to the first paragraph may mean that implementation of the necessary measures is delayed. The expenses incurred by the supervisory authority are enforceable by execution proceedings.

§ 22 Fees The King may issue regulations relating to fees for processing applications for approval pursuant to this Act or regulations laid down pursuant thereto, and relating to supervisory measures implemented to ensure compliance with the Act or decisions pursuant thereto. Fees are enforceable by execution proceedings.

3 of 4 14.10.2011 08:24

Gene Technology Act - regjeringen.no http://www.regjeringen.no/en/doc/Laws/Acts/Gene-Technology-Act.htm...

§ 23 Compensation Any person responsible for activities pursuant to the present Act is liable to pay compensation regardless of any fault on his part if his activities cause damage, nuisance or loss through the deliberate or unintended release of genetically modified organisms into the environment.

Moreover, the provisions of Chapter 8 of the Pollution Control Act concerning compensation for pollution damage apply insofar as they are appropriate. The supervisory authority pursuant to the present Act takes the place of the pollution control authority pursuant to section 58 of the Pollution Control Act. The instance authorised to grant approval pursuant to the present Act takes the place of the pollution control authority pursuant to section 63, second and third paragraphs, of the Pollution Control Act.

§ 24 Coercive fines In the event of contravention of conditions, orders or prohibitions issued pursuant to this Act, the King may impose a coercive fine that continues to be effective for as long as the contravention continues. A coercive fine is enforceable by execution proceedings.

§ 25 Penal measures Any person who wilfully or through negligence contravenes provisions set out in or issued pursuant to this Act or decisions made pursuant to the said provisions is liable to fines or imprisonment for a term not exceeding one year.

If there are especially aggravating circumstances, imprisonment for a term not exceeding four years may be imposed.

An attempt to commit such an offences or aiding and abetting therein are subject to a penalty. Contravention of the first paragraph is considered to be a misdemeanour.

Chapter 5 The Norwegian Biotechnology Advisory Board § 26 The Norwegian Biotechnology Advisory Board The King will appoint a board that on request or on its own initiative shall give opinions on matters that come within the scope of this Act and other questions relating to biotechnology. The opinions of the board are public unless otherwise required by the statutory duty of secrecy. Section 12 of this Act applies correspondingly to the opinions of the board.

Chapter 6 Final provisions § 27 Entry into force This Act enters into force on the date decided by the King. It may be decided that different parts of the Act enter into force at different times.

§ 28 Transitional provisions

§ 29 Amendments to other Acts

External link: Text of the law (in Norwegian)

4 of 4 14.10.2011 08:24